We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
- Authors
Hermansen, K.; Bækdal, T. A.; Düring, M.; Pietraszek, A.; Mortensen, L. S.; Jørgensen, H.; Flint, A.
- Abstract
Aims Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady-state liraglutide 1.8 mg versus placebo on postprandial plasma lipid concentrations after 3 weeks of treatment in patients with type 2 diabetes mellitus (T2DM). Methods In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m2) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo. After each 3-week period, a standardized fat-rich meal was provided, and the effects of liraglutide on triglyceride (primary endpoint AUC0-8h), apolipoprotein B48, non-esterified fatty acids, glycaemic responses and gastric emptying were assessed. ClinicalTrials.gov ID: NCT00993304. Funding: Novo Nordisk A/S. Results After 3 weeks, mean postprandial triglyceride (AUC0-8h liraglutide/placebo treatment-ratio 0.72, 95% CI [0.62-0.83], p = 0.0004) and apolipoprotein B48 (AUC0-8h ratio 0.65 [0.58-0.73], p < 0.0001) significantly decreased with liraglutide 1.8 mg versus placebo, as did iAUC0-8h and Cmax (p < 0.001). No significant treatment differences were observed for non-esterified fatty acids. Mean postprandial glucose and glucagon AUC0-8h and Cmax were significantly reduced with liraglutide versus placebo. Postprandial gastric emptying rate [assessed by paracetamol absorption (liquid phase) and the 13C-octanoate breath test (solid phase)] displayed no treatment differences. Mean low-density lipoprotein and total cholesterol decreased significantly with liraglutide versus placebo. Conclusions Liraglutide treatment in patients with T2DM significantly reduced postprandial excursions of triglyceride and apolipoprotein B48 after a fat-rich meal, independently of gastric emptying. Results indicate liraglutide's potential to reduce CVD risk via improvement of postprandial lipaemia.
- Subjects
TYPE 2 diabetes treatment; TRIGLYCERIDES; APOLIPOPROTEIN B; PLACEBOS; UNSATURATED fatty acids; RANDOMIZED controlled trials
- Publication
Diabetes, Obesity & Metabolism, 2013, Vol 15, Issue 11, p1040
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.12133